Global Prostate Health Market Outlook to 2028

Global Prostate Health Market Overview

The Global Prostate Health Market was valued at USD 38.6 billion in 2023. The market growth is primarily driven by the rising prevalence of prostate diseases, such as benign prostatic hyperplasia (BPH) and prostate cancer, which are increasingly common among aging populations globally. The advancements in diagnostic techniques, coupled with heightened awareness and screening programs, have significantly contributed to the markets expansion.

Key players in the market are Pfizer Inc., Eli Lilly and Company, Astellas Pharma Inc., Glaxo Smith Kline plc, and Abb Vie Inc. These companies are involved in the development and marketing of drugs, devices, and therapies aimed at managing prostate health, particularly in treating conditions such as BPH and prostate cancer.

In August 2022, Pfizer Inc. announced the FDA approval of Orgovyx (relugolix) for the treatment of advanced prostate cancer.This milestone represents a significant advancement in prostate cancer therapy, providing patients with a new oral treatment option that can help manage the disease and improve quality of life.

North America, particularly the United States, dominates the Global Prostate Health Market, with the high prevalence of prostate-related diseases, well-established healthcare infrastructure, and significant investment in research and development. The presence of key players and the early adoption of innovative treatments further strengthen the regions leading position.

Global Prostate Health Market Segmentation

The market is segmented into various factors like treatment, disease, and region.

By Treatment: The market is segmented by treatment type into medication, surgery, and others. In 2023, medication held a dominant market share due to the widespread use of alpha-blockers and 5-alpha-reductase inhibitors, which are the first-line treatment for conditions such as BPH.

By Disease: The market is segmented by disease type into benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis. In 2023, benign prostatic hyperplasia (BPH) had the largest market share, with the demand for effective treatment options. The development of new pharmacological therapies, along with the availability of minimally invasive surgical procedures, has further strengthened the dominance of this segment.

By Region: The market is segmented by region into North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and Latin America. In 2023, North America dominated the market with the rising incidence of prostate diseases, combined with increasing healthcare expenditures and growing awareness, is driving the demand for prostate health solutions in the region.

Global Prostate Health Market Competitive Landscape

Company

Establishment Year

Headquarters

Pfizer Inc.

1849

New York, USA

Eli Lilly and Company

1876

Indianapolis, USA

Astellas Pharma Inc.

2005

Tokyo, Japan

Glaxo Smith Kline plc

2000

Brentford, UK

Abb Vie Inc.

2013

North Chicago, USA

Eli Lilly and Company: Eli Lilly is expanding into nuclear isotope production to enhance cancer treatments, particularly for prostate cancer. This strategic move aims to support the development of radiopharmaceuticals, potentially improving outcomes for patients. The initiative reflects a growing trend in integrating advanced technologies into cancer care.

Astellas Pharma Inc.: Astellas' Xtandi (enzalutamide) has received European Commission approval for treating additional recurrent early prostate cancer settings. This decision is based on data from the ARCHES trial, which demonstrated a significant reduction in the risk of radiography, enhancing treatment options for patients.

Global Prostate Health Market Analysis

Market Growth drivers

Increasing Incidence of Prostate Disorders: The global incidence of prostate disorders, particularly prostate cancer and benign prostatic hyperplasia (BPH), is on the rise, significantly driving the demand for prostate health management solutions. In 2023, the World Health Organization (WHO) reported over 1.4 million new cases of prostate cancer worldwide, with a substantial proportion occurring in developed regions such as North America and Europe.

Advancements in Diagnostic Technologies: Recent advancements in diagnostic technologies have significantly improved the early detection and management of prostate disorders, contributing to the growth of the prostate health market. In 2024, the introduction of next-generation sequencing (NGS) and liquid biopsy techniques enabled more precise and less invasive detection of prostate cancer. These technologies have been rapidly adopted in leading healthcare markets, including the United States.

Rising Healthcare Expenditure: In 2024, global healthcare spending reached USD 9 trillion, driven by significant investments in public health infrastructure and the expansion of healthcare services in emerging economies. This increase in spending has facilitated the wider availability of prostate health services, including diagnostics, treatment, and ongoing care, particularly in countries like China and India, where government initiatives have prioritized the early detection and treatment of prostate disorders.

Market Challenges

Limited Access to Healthcare in Developing Regions: Access to healthcare services remains limited in many developing regions, which poses a challenge to the growth of the prostate health market. This lack of access is exacerbated by inadequate healthcare infrastructure, shortages of medical professionals, and low levels of awareness about prostate health.

Lack of Awareness and Stigma: A lack of awareness and stigma associated with prostate disorders, particularly in certain cultural contexts, remains a significant challenge in the market. Furthermore, cultural stigmas around discussing men's health issues, particularly those related to the prostate, can prevent individuals from seeking timely medical advice and treatment.

Government Initiatives

European Union's Prostate Cancer Initiative: The European Union's Prostate Cancer Initiative, known as PRAISE-U, aims to reduce prostate cancer mortality through smart early detection. Launched in April 2023, this three-year project involves 25 institutions across 12 countries, focusing on developing tailored screening algorithms to avoid overdiagnosis while improving early detection rates.

India's Prostate Cancer Screening Initiative: India's Prostate Cancer Screening Initiative aims to enhance awareness and early detection of prostate cancer among men, particularly those over 50. The initiative focuses on promoting PSA testing and education about prostate health, addressing the rising incidence of prostate cancer in the country, which is the third most common cancer among Indian men.

Global Prostate Health Market Future Outlook

The future trends in the Global prostate health industry include the growth in precision medicine for prostate cancer, the expansion of telemedicine services for prostate health, the adoption of artificial intelligence in diagnostics, and the expansion of prostate health services in emerging markets.

Future Market Trends

Growth in Precision Medicine for Prostate Cancer: The future of the prostate health market will be significantly shaped by the continued growth of precision medicine, which involves tailoring treatments based on individual genetic profiles. By 2028, it is estimated that precision medicine will account for 35% of prostate cancer treatments globally, driven by advances in genetic testing and biomarker analysis.

Expansion of Telemedicine Services for Prostate Health: Telemedicine is expected to play an increasingly important role in prostate health management over the next five years. By 2028, the global telemedicine market for prostate health is projected to grow significantly, with an estimated 15 million virtual consultations conducted annually. This growth will be driven by the need for accessible and convenient healthcare services, particularly in regions with limited access to specialist care.
Please Note: It will take 5-7 business days to complete the report upon order confirmation